MEDVi vs Ro: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

MEDVi beats Ro overall, scoring 7.7/10 vs 7.2/10. Ro is more affordable at $149/mo vs $299/mo. Choose MEDVi for users who want a low entry price with oral and injectable co. Choose Ro for users who want fda-approved brand-name glp-1 access includin.

A side-by-side comparison of MEDVi and Ro covering pricing, scores, medication types, insurance, and more to help you decide.

Higher Rated

MEDVi

#22 of 48

7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake — one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi

Ro

#44 of 48

7.2/10

One of the most recognized telehealth brands, now restructured: Ro Body membership ($149/mo ongoing or $74/mo annual prepay) is priced separately from medication. Added Foundayo (Eli Lilly's FDA-approved oral GLP-1 launched April 6, 2026) alongside Wegovy, Zepbound, Ozempic, and Mounjaro.

Visit Ro

Feature	MEDVi	Ro
Our Score	7.7/10	7.2/10
Starting Price	$299/mo	$149/mo
Medication Type	Both	Brand
Insurance Accepted	No	Yes
Best For	Users who want a low entry price with oral and injectable compounded options	Users who want FDA-approved brand-name GLP-1 access including the new Foundayo (orforglipron) oral pill, with direct insurance billing
Ranking	#22	#44

Pros & Cons Compared

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

−Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms

Ro

Pros

+Carries Foundayo (orforglipron) — Eli Lilly's FDA-approved oral GLP-1 launched April 6, 2026 — at $149-299/mo via LillyDirect matching
+Direct insurance billing with major carriers — with coverage, Wegovy or Zepbound can cost $0-25/mo copay
+Ro Body membership: $39 first month, $149/mo ongoing, or $74/mo on annual prepay ($100/mo savings)
+Claims matched pricing with LillyDirect, NovoCare, and TrumpRx — some of the lowest cash brand prices available

Cons

−Membership and medication are billed separately — readers need to add them together for the all-in monthly cost
−Brand-name only — no compounded semaglutide or tirzepatide (compounded 'limited' footnote from prior years is not reliably offered now)
−Without insurance, brand-name meds stack on top of the $149 membership ($199+ intro, $349+ ongoing for Wegovy injection)

Our Verdict

MEDVi edges out Ro with a score of 7.7/10 vs 7.2/10. If budget is your priority, Ro starts at $149/mo compared to MEDVi's $299/mo. Ro accepts insurance, which can significantly reduce your out-of-pocket costs. MEDVi offers both brand-name and compounded medications, giving you more flexibility. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options. Choose Ro if you want: users who want fda-approved brand-name glp-1 access including the new foundayo (orforglipron) oral pill, with direct insurance billing.

Still undecided? Editor's #1 Overall Pick

Eden Health GLP-1

$249/mo · 8.9/10 · Both

If neither MEDVi nor Ro feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Eden Health GLP-1 — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Eden Health GLP-1→Read our full Eden Health GLP-1 review